Sign in
CompletedNo phase

Role of 18F-FDG PET/CT in the Evaluation of Cavernous Sinus Syndrome: a Pilot Study

Key facts

Who runs it
Post Graduate Institute of Medical Education and Research, Chandigarh
Where
India1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
54 people enrolled
Started
1 Jul 2022
Ended
30 Jun 2024
Type of study
Observational
Treatments tested
  • FDG radiotracer
Record updated
6 December 2024

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (6)Hide the full registry criteria

Who can take part

  • Patients with age greater than or equal to 18 years,
  • with newly diagnosed CSS,
  • lesion seen on MRI in the CS, and
  • willing to give written informed consent

Who cannot take part

  • Patients already being treated (including steroids)
  • Pregnant and lactating patients

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Cavernous sinus syndrome (CSS) can be caused by a wide range of inflammatory, malignant, benign, vascular and miscellaneous disorders. Even after modern advances, reaching the final etiological diagnosis remains a challenge in CSS. This study is planned to determine the role and incremental value of 18F-FDG PET/CT in characterising different cavernous sinus pathologies based on their metabolic activity and detecting extracranial involvement.

The group in the trial

  • Treatment naive patients presenting with Cavernous Sinus Syndrome with cavernous sinus lesion on MRI

    Treatment: FDG radiotracer

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
6 December 2024